Skip to main content
. 2008 May 20;295(2):E278–E286. doi: 10.1152/ajpendo.00028.2008

Fig. 1.

Fig. 1.

Effect of icv administration of human relaxin-2 (H2, 5 nmol), human relaxin-3 (H3, 5 nmol), and H3 (5 nmol) with gonadotropin-releasing hormone (GnRH) antagonist (200 nmol) on plasma luteinizing hormone (LH, ng/ml; A), plasma follicle-stimulating hormone (FSH, ng/ml; B), and total plasma testosterone (nmol/l; C) at 30 min postinjection in male adult rats. *P < 0.05, ***P < 0.001, and δδδP < 0.001 by ANOVA with post hoc Tukey's test, n = 10/group.